Abstract
Abstract
Background
Berberine (Ber) is a herbal alkaloid with pharmacological activity in general and a high anticancer potency in particular. However, due to its low bioavailability, the difficulty in reaching a target and choosing the right dose, there is a need to improve approaches of Ber use in anticancer therapy. In this study, Ber, noncovalently bound to a carbon nanostructure C60 fullerene (C60) at various molar ratios of the components, was explored against Lewis lung carcinoma (LLC).
Methods
C60–Ber noncovalent nanocomplexes were synthesized in 1:2, 1:1 and 2:1 molar ratios. Ber release from the nanocomplexes was studied after prolonged incubation at different pH with the liquid chromatography–mass spectrometry analysis of free Ber content. Biological effects of the free and C60-complaxated Ber were studied in vitro towards LLC cells with phase-contrast and fluorescence microscopy, flow cytometry, MTT reduction, caspase activity and wound closure assays. The treatment with C60–Ber nanocomplex was evaluated in vivo with the LLC-tumored C57Bl mice. The mice body weight, tumor size, tumor weight and tumor weight index were assessed for four groups, treated with saline, 15 mg C60/kg, 7.5 mg Ber/kg or 2:1 C60-Ber nanocomplex (15 mg C60/kg, 7.5 mg Ber/kg).
Results
Ber release from C60–Ber nanocomplexes was promoted with medium acidification. LLC cells treatment with C60–Ber nanocomplexes was followed by enhanced Ber intracellular uptake as compared to free Ber. The cytotoxicity of the studied agents followed the order: free Ber < 1:2 < 1:1 < 2:1 C60–Ber nanocomplex. The potency of cytotoxic effect of 2:1 C60–Ber nanocomplex was confirmed by 21.3-fold decrease of IC50 value (0.8 ± 0.3 µM) compared to IC50 for free Ber (17 ± 2 µM). C60–Ber nanocomplexes induced caspase 3/7 activation and suppressed the migration activity of LLC cells. The therapeutic potency of 2:1 C60–Ber nanocomplex was confirmed in a mouse model of LLC. The tumor growth in the group treated with 2:1 C60–Ber nanocomplex is suppressed by approximately 50% at the end of experiment, while in the tumor-bearing group treated with free Ber no therapeutic effect was detected.
Conclusions
This study indicates that complexation of natural alkaloid Ber with C60 may be a novel therapeutic strategy against lung carcinoma.
Graphical abstract
Funder
Brandenburg programme “Strengthening technological and application-oriented research at scientific institutions (StaF Directive)”
National Research Foundation of Ukraine
Ukrainian-Chinese Intergovernmental Science
Open Access Publication Funds by the German Research Foundation and of the Technical University of Applied Sciences Wildau
Technische Hochschule Wildau
Publisher
Springer Science and Business Media LLC
Subject
Physical and Theoretical Chemistry,Pharmaceutical Science,Oncology,Biomedical Engineering
Reference62 articles.
1. Bao J, Huang B, Zou L, Chen S, Zhang C, Zhang Y et al (2015) Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents. PLoS ONE 10(9):e0139298
2. Borowik A, Prylutskyy Y, Kawelski Ł, Kyzyma O, Bulavin L, Ivankov O et al (2018) Does C60 fullerene act as a transporter of small aromatic molecules? Colloids Surf B Biointerfaces 164:134–143
3. Cai Y, Xia Q, Luo R, Huang P, Sun Y, Shi Y et al (2014) Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med 68(1):53–62
4. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47(4):936–942
5. Chaturvedi VK, Singh A, Singh VK, Singh MP (2019) Cancer nanotechnology: a new revolution for cancer diagnosis and therapy. CDM 20(6):416–429
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献